Business
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023 Lausanne, Switzerland, March 8, 2023 – AC Immune SA
About this update from Ac Immune Sa
[{"type":"text","content":"AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023 Lausanne, Switzerland, March 8, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will issue a press release to report its full year 2022 financial results and provide a corporate update on March 16, 2023 at 7:00am ET. Thereafter, Company management will be available for one-on-one calls with investors and analysts to discuss the results and outlook for 2023. About AC Immune SA AC Immune SA is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and others, resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments. SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU. The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release. For further information, please contact: Head of Investor Relations & Corporate CommunicationsGary Waanders, Ph.D., MBAAC ImmunePhone: +41 21 345 91 91Email: [email protected]. InvestorsCorey Davis, Ph.D.LifeSci AdvisorsPhone: +1 212 915 2577 Email: [email protected] MediaChris MaggosCohesion BureauPhone: +41 79 367 6254Email: [email protected] Forward looking statementsThis press release contains statements that const...